Endocrine Abstracts

Contents

• 22nd Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2024
• • Oral Communications
  • • ⁶⁸Ga68 DOTATATE imaging on a whole-body PET/CT scanner & optimising injected activity

      ea0105oc1
    • The biopsychosocial impact of pancreatic enzyme replacement therapy shortages

      ea0105oc2
    • Emergency and routine presentation of neuroendocrine neoplasia in England: determinants of diagnosis and survival outcomes

      ea0105oc3
    • Clustering of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) using machine learning (ML) and comparison with Tumour, Node, Metastasis (TNM) staging: a retrospective, population-based study using Surveillance, Epidemiology, and end results (SEER)

      ea0105oc4
    • Selective internal radiotherapy (SIRT) versus hepatic artery embolization (HAE) for the treatment of neuroendocrine liver metastases

      ea0105oc5
  • Poster Presentations
  • • Clinical outcomes of streptozocin (STZ) based chemotherapy in neuroendocrine tumours (NETs): a retrospective analysis of 26 patients from a single cancer centre - nottingham university hospitals (UK)

      ea0105p1
    • Insulinoma: an argument for rapid PRRT pathways in refractory disease

      ea0105p2
    • Primary hyperparathyroidism in multiple endocrine neoplasia type 1 (MEN1): Northern Ireland's (N.I) experience

      ea0105p3
    • Leak rates in pancreatico-duodenectomy procedures in pancreatic NETs compared to pancreatic ductal adenocarcinoma resections

      ea0105p4
    • Management of cold sepsis in a patient receiving peptide radionuclide receptor treatment (PRRT): a case review

      ea0105p5
    • The experience of transarterial embolisation for metastsatic NET at queen Elizabeth Hospital Birmingham and future possible role of selective internal radiation therapy

      ea0105p6
    • Coeliac artery dissection in neuroendocrine neoplasms: coincidence or cause?

      ea0105p7
    • The indolent behaviour of type 1 gastric neuroendocrine tumours smaller than 1 cm: a single western center experience

      ea0105p8
    • Clinical outcomes of patients with rectal neuroendocrine tumours smaller than 10 mm after endoscopic resection

      ea0105p9
    • Testicular neuroendocrine tumour with carcinoid heart diseaseon the background of urological cancers: a trio of malignancies

      ea0105p10
    • Is there a role for post-operative functional imaging in small intestinal neuroendocrine tumours resected with curative intent?

      ea0105p11
    • From PRRT to liver transplant: redefining boundaries and navigating multimodal management of metastatic duodenal NET

      ea0105p12
    • A pilot model of group education for nutritional/dietary advice and symptom management in neuroendocrine neoplasms (NEN) (GEDNEN course interim analysis)

      ea0105p13
    • Treatment of MiNEN with peptide receptor radionuclide therapy

      ea0105p14
    • Impact of somatostatin analogues on SSTR expression and Ki-67 expression marker in LCC-18 neuroendocrine tumour cells

      ea0105p15
    • Case report: immunotherapy for a well-differentiated rectal neuroendocrine neoplasm

      ea0105p16
    • High prevalence of sarcopenia in patients with neuroendocrine tumours and carcinoid heart disease, but no effect on postoperative complications or survival

      ea0105p17
    • Retrospective audit evaluating outcomes in patients post resection for pancreatic neuroendocrine tumours

      ea0105p18
    • Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): insights from national cancer registration and analysis service (NCRAS)

      ea0105p19
    • See the unseen: a rare presentation of metastatic small bowel NET with unilateral visual loss

      ea0105p20
    • Size, but not the number of positive lymph nodes is associated with worse overall survival in patients with small bowel neuroendocrine tumours

      ea0105p21
    • Advocacy in practice: pancreatic enzyme replacement therapy

      ea0105p22
    • Profound, durable benefit from external beam radiotherapy for primary, in transit and locoregional disease from Merkel cell carcinoma in the frail elderly: illustrative clinical vignettes

      ea0105p23
    • Challenging diagnosis of intra-pancreatic splenunculus mimicking neuroendocrine tumour

      ea0105p24
    • Management of carcinoid flare events following peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NET): our experience at the christie NHS foundation trust

      ea0105p25
    • Challenges in diagnosis and treatment in an evolving pancreatic neuroendocrine tumour

      ea0105p26
    • Multifocal small bowel neuroendocrine tumours - experience of a single clinical centre

      ea0105p27
    • Case series: tuberous sclerosis associated pancreatic neuroendocrine tumours at a tertiary centre

      ea0105p28
    • Phaeochromocytoma associated with neurofibromatosis type 1: a single tertiary care centre experience

      ea0105p29
    • Malnourished patients with GEP-NETs, how does this develop in 5 years

      ea0105p30
    • Retrospective study evaluating factors influencing cancer recurrence following surgical resection of pancreatic neuroendocrine tumours (PanNETs)

      ea0105p31
    • Perioperative short-acting somatostatin analogue use in patients undergoing neuroendocrine tumour excision - do we need a change in guidelines?

      ea0105p32
    • Hidden hypoglycemia: a case series on diagnosing insulinomas

      ea0105p33